22/09/2025
Shareholder Webinar – September 18, 2025
In this video, the OSE team presents its ambition and innovation, its key leverages, the 2025–2028 strategy, and answers shareholders' questions.
08/09/2025
Edison – Executive Interview: Silvia Comis MD, Chief Clinical and Medical Research Officer (September 8th, 2025)
In this interview, @Silvia Comis MD, Chief Clinical and Medical Research Officer at OSE Immunotherapeutics, covers the Company’s lead immuno-oncology candidate, Tedopi®. She also discusses the ongoing registrational Phase 3 ARTEMIA programme, alongside several other Phase 2 programmes in different cancer indications run by academic groups. She concludes by highlighting the key upcoming catalysts and milestones.
01/09/2025
Edison – Executive Interview : Sonya Montgomery, Chief Development Officer (September 1st 2025)
Edison Group a publié une 'Executive Interview' de Sonya Montgomery, chief development officer chez OSE Immunotherapeutics ; cette interview porte sur Lusvertikimab, le candidat phare de la société en immuno-inflammation, et met en lumière les principaux catalyseurs et jalons à venir.